Levofolic

Levoleucovorin Disodium, the active ingredient in Levofolic, is a folate analog presented as an injectable solution for intravenous use. It is employed to mitigate toxicity from certain chemotherapeutic agents and to support folate metabolism in patients requiring supplementation.

GNH USA supplies Levofolic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU GMP standards and provides secure cold‑chain logistics for the product.

Levofolic (levoleucovorin disodium) is used primarily in oncology and supportive care to address folate‑related pathways.

- Methotrexate toxicity: reduces cellular damage and accelerates recovery after high‑dose methotrexate therapy. - 5‑Fluorouracil‑based chemotherapy: enhances antitumor activity by stabilizing the binding of 5‑FU to thymidylate synthase. - Folate deficiency: restores normal folate levels in patients with inadequate dietary intake or malabsorption.

Levofolic may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Vomiting - Mild rash or erythema - Flushing or warmth sensation - Headache - Elevated liver enzymes

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypersensitivity (e.g., angioedema) - Acute renal impairment - Hypotension or shock - Cardiac arrhythmias - Thromboembolic events

When using Levofolic, consider the following precautions:

- Assess renal function: adjust use in patients with impaired clearance. - Monitor liver enzymes: watch for hepatotoxicity during prolonged therapy. - Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in pregnancy: only if benefits outweigh risks. - Avoid concurrent high‑dose antifolates without medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofolic can interact with several medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Pemetrexed: levoleucovorin may reduce antitumor efficacy of pemetrexed. - High‑dose methotrexate (outside rescue protocol): can interfere with intended toxicity. - Folate antagonists (e.g., trimethoprim‑sulfamethoxazole): may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: levoleucovorin can enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: folate supplementation may reduce hormonal efficacy. - NSAIDs: combined use may increase risk of renal dysfunction.